ASHP: SVP, Injectable Opioid Shortages Threaten Patient Care

Share this content:
ASHP: SVP, Injectable Opioid Shortages Threaten Patient Care
ASHP: SVP, Injectable Opioid Shortages Threaten Patient Care

THURSDAY, May 31, 2018 (HealthDay News) -- The widespread shortages of injectable opioids and small-volume parenteral (SVP) solutions are jeopardizing patient care and placing a strain on hospital operations, according to a report published by the American Society of Health-System Pharmacists (ASHP).

ASHP members were surveyed in April 2018 to examine recovery of the SVP solution shortage and the impact of the acute shortage of injectable opioids. The survey contained 16 questions and was informal and nonscientific. A total of 343 responses were obtained.

According to ASHP, 98.4 percent of respondents reported experiencing severe or moderate shortages of morphine, hydromorphone, and fentanyl. Hospitals are managing the shortages by switching to oral opioids, restricting injection opioid use, prioritizing patients according to clinical need, and converting to non-opioid medications. In this survey, 86.4 percent of respondents reported being affected by the SVP shortage, compared with 99.1 percent in November 2017.

"The ongoing shortages of these vital lifesaving medications are overwhelming the resources of our nation's hospitals, placing our health care system on the brink of a public health emergency," ASHP Chief Executive Officer Paul W. Abramowitz, Pharm.D., Sc.D., said in a statement. "Congress must act now to implement remedies that will address the underlying causes of drug shortages and ensure that patients have access to the medications they need."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Disease-carrying ticks were detected in 83 counties where they'd never been found before

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from $208 to $32 from 2004 to 2016

Visual Function Deficits Up in Developmental Dyslexia

Visual Function Deficits Up in Developmental Dyslexia

Increased prevalence of deficits in visual function versus typically developing school-age children

is free, fast, and customized just for you!




Already a member?

Sign In Now »